DUBLIN--(BUSINESS WIRE)--The "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Peripheral Arterial Disease Peripheral Vascular Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD) and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 1, 11, 9, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered
- Introduction
- Overview
- Therapeutics Development
- Therapeutics Assessment
- Companies Involved in Therapeutics Development
- Drug Profiles
- Dormant Projects
- Discontinued Products
- Product Development Milestones
- AlfaSigma SpA
- AnGes Inc
- ARCA biopharma Inc
- Athera Biotechnologies AB
- Athersys Inc
- Bayer AG
- Betagenon AB
- BiogenCell Ltd
- CardioVascular BioTherapeutics Inc
- Celularity Inc
- Diffusion Pharmaceuticals Inc
- Hemostemix Inc
- Human Stem Cells Institute
- ID Pharma Co Ltd
- Juventas Therapeutics Inc
- LipimetiX Development Inc
- Novartis AG
- Proteon Therapeutics Inc
- Recardio GmbH
- Resverlogix Corp
- Reven Pharmaceuticals Inc
- Stemedica Cell Technologies Inc
- Symic Biomedical Inc
- VESSL Therapeutics Ltd
- ViroMed Co Ltd
- Yuyu Pharma Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lrsd5b/peripheral?w=4
